## Community Engagement in Healthcare Using Clinical Trials

Jorge Gomez, MD, PhD

Assistant Vice President for Research

Assistant Professor, Dept of Translational Medical Sciences

School of Medicine

Health Sciences Center

Texas A&M University

October 4, 2023



## Health Equity, Inequity, and Disparities



## Definitions

- Health Equity: Attainment of the highest level of health for all people. Health Equity means efforts to ensure that all people have full and equal access to opportunities that enable them to lead healthy lives.
- Health Inequities: Differences in health that are avoidable, unfair, and unjust. Health inequities are affected by social, economic, and environmental conditions.
- Health Disparities: unequal burden of disease in a population due to race, ethnicity, gender, education, socioeconomic status, disability, geographic location, sexual orientation, cultural or religious beliefs (DHHS)



Community Engagement in Healthcare Using Clinical Trials


## History and Ethics: Ethnic Minority Engagement in Research

#### Hispanic in the US

#### Background

- Hispanic/Latinx population in the US: >60M (USCB, 2020)
- Heterogenous group:
  - Diverse national origin
  - Racial makeup
  - Genetic ancestry
  - Modifiable risk factors
  - Environmental exposures
  - Lower SES, acculturation
  - Higher burden of disease: Diabetes, Cancer, Infectious, among others
  - Higher uninsured, underinsured, limited access to health care
  - Lower survival rates
  - Leading cause of death in childhood and adolescence
  - Low participation in clinical trials








## Accurate prescribing through genetics. Normal dosage response. Lower dosage response. Higher dosage response. No response. Alternative drug recommended. Drug is toxic. Alternative drug recommended.







## History and Ethics: Ethnic Minority Engagement in Research

- Clinical Trials (CT): an important tool to provide novel treatments, diagnoses, and supportive interventions to patients
- Patients that participate in CT receive benefits of closed monitoring of disease and better patient outcomes
- Through CT, researchers and patients might gain a better understanding of individualized treatments and disease management
- Patient heterogeneity factors can be taken into account when participating in CT and contribute to a better understanding of therapy responses and disease management



## History and Ethics: Ethnic Minority Engagement in Research

#### Hispanic Participation in Clinical Trials: Race and Ethnicity

- Hispanics account for 2-3% of participation in CT
- Race and Ethnicity contribute to underreporting of Hispanics in CT
- Classifying Hispanics as one ethnic group is a problem by itself
- Hispanics vs Latinos means different things for different people in terms of heritage, ancestry, and place of origin, and does not differentiate from others in the Caribbean and other regions in Central and South America

The use of Hispanic/Latino term underestimates the diversity and heterogeneity of the population and its impact on disease risk, health behaviors, and outcomes



## History and Ethics: Ethnic Minority Engagement in Research

## Hispanic Participation in Clinical Trials: Federal Government

## Federal Act of 2017 (FDAAA81):

- Requires reporting of racial/ethnic demographic data in all federallysponsored CTs.
- It does not address self-reporting
- It does not address subgroups
- It does not provide guidance for methodologies of data gathering and enrollment



History and Ethics: Ethnic Minority Engagement in Research

## Barriers to Enrollment of Hispanics in CTs

### **Hispanic Patients**

- Lack of awareness
- Fear of being a "guinea pig", side-effects, placebo effect
- Underinsured, unsinured
- Low SES, education, knowledge
- Lack of access to academic clinical centers, transportation
- Communication barriers, language (English proficiency, low literacy)
- Complexity of protocol design
- New immigrants

## Health care providers

- Physician preference, unconscious bias
- Fear of losing patients
- Lack of CT awareness, interest in contributing to CTs
- Lack of culturally competent staff, bilingual
- Source of funding (pharma vs academic)



History and **Ethics:** Ethnic Minority Engagement in Research

## Barriers to Enrollment of Hispanics in CTs: Addressing the Problem

- Implement culturally appropriate outreach and education programs at the local level
- Improve informed consent process, including appropriate translation
- Use of the patient navigator program
- Build community partnerships
- Learn to know your community's origin
- Establish trust with the community leaders
- Educate the health care staff and increase their cultural competence

Business as usual neglects or minimizes the social conditions in which the research is being conducted



# History and Ethics: Ethnic Minority Engagement in Research

Barriers to Enrollment of Hispanics in CTs: Ethical Responsibility


- In general, minority communities are vulnerable populations
- Evidence-based research must be derived from the population at large, not from subgroups
- Understanding community-based knowledge is of paramount importance to promoting CT in minority communities, including the Hispanic community

To promote population health, researchers must step out of their comfort zone of a protected and privileged class (educated, knowledgeable, resourceful, usually white population) and involve all sectors of society.

Clinical research should incorporate the upstream factors causing health disparities and adapt novel interventions in real-life settings taking into account the community knowledge they serve.

These strategies will help researchers to initiate trust, strengthen human dignity, and ensure mutual benefits for researchers and the community they serve.







Addressing Cancer Health Disparities in Latinos via Clinical Trials Dege Come Refer for Commerce Refer for C



Addressing Cancer Health Disparities in Latinos via Clinical Trials (diaglobal.org)



#### Driving Diversity and Inclusion in Cancer Drug Development – Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges

Lola A. Fashoyin-Aje<sup>1</sup>, Craig Tendler<sup>2</sup>, Bea Lavery<sup>3</sup>, Serban Ghiorghiu<sup>4</sup>, Brittany Gerald<sup>5</sup>, Chitkala Kalidas<sup>6</sup>, Nicole Richie<sup>3</sup>, Kathleen Winson<sup>3</sup>, Nicholas J.H. Warren<sup>7</sup>, Tristen V. Tellman<sup>7</sup>, Jon Retzlaff<sup>7</sup>, Margaret Foti<sup>8</sup>, and Richard Pazdur<sup>1</sup> Clin Cancer Res 2023;29:3566–72

DOI: 10.1158/1078-0432.CCR-23-1391

#### Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement

Randall A. Oyer, MD1; Patricia Hurley, MSc2; Leigh Boehmer, PharmD3; Suanna Steeby Bruinooge, MPH2; Kathryn Levit, PhD2; Nadine Barrett, PhD4; Al Benson, MD5; Lea Ann Bernick, MHA6; Leslie Byatt7; Marjory Charlot, MD, MPH, MSc8; Jennie Crews, MD9; Kyle DeLeon10; Lola Fashoyin-Aje, MD, MPH11; Elizabeth Garrett-Mayer, PhD2; Julie R. Gralow, MD2; Sybil Green, JD, RPh, MHA2; Carmen E. Guerra, MD, MSCE12; Leila Hamroun13; Claudia M. Hardy, MPA14; Bridgette Hempstead15; Sanford Jeames, DHA16; Mel Mann, MBA, MEd17; Khalid Matin, MD18; Worta McCaskill-Stevens, MD, MS19; Janette Merrill, MSEd2; Grzegorz S. Nowakowski, MD20; Manali I. Patel, MD, MPH, MS21; Alice Pressman, PhD, MS22; Amelie G. Ramirez, DrPH, MPH23; Juanita Segura, BSc24; Barbara Segarra-Vasquez, DHSc25; Jen Hanley Williams, MA2; James E. Williams Jr, MS26; Karen M. Winkfield, MD, PhD27; Eddy S. Yang, MD, PhD28; Victoria Zwicker, MPH3; and Lori J. Pierce, MD29

Journal of Clinical Oncology 2022;40:19:2163 DOI https://doi.org/10. 1200/JCO.22.00754



#### From: Driving Diversity and Inclusion in Cancer Drug Development – Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges

Clin Cancer Res. 2023;29(18):3566-3572. doi:10.1158/1078-0432.CCR-23-1391

